Advertisement

Prostatakarzinom

  • Th. Buhleier
  • D. Zierhut
Chapter

Zusammenfassung

Das Risiko, während des Lebens an einem Prostatakarzinom zu erkranken, beträgt in den USA nach der aktuellsten Untersuchung 1 : 6. Hier ist das Prostatakarzinom für 13 % aller Krebstodesfälle verantwortlich. Epidemiologische Daten zeigen eine stark altersabhängige Inzidenz des Prostatakarzinoms. In der Altersgruppe der 30- bis 35-Jährigen liegt die Inzidenz bei 1/100.000. Der Gipfel dieser Erkrankung liegt bei 1/1.733 in der Altersgruppe der 65- bis 66-Jährigen (Gemeinsames Krebsregister 2005). Zur Zeit versterben in Deutschland etwa 12.000 Männer an einem Prostatakarzinom (Bögermann et al. 2010). Verantwortlich für den rasanten Anstieg der Detektion des Prostatakarzinoms in der Vergangenheit waren vor allem die verbesserten Früherkennungsprogramme . Seit der Entdeckung des prostataspezifischen Antigens PSA , eines zur Früherkennung und Verlaufsbeurteilung des Prostatakarzinoms geeigneten Bluttests werden mehr Prostatakarzinomträger in frühen Erkrankungsstadien diagnostiziert. Trotzdem bleibt zum jetzigen Zeitpunkt festzuhalten, dass nicht eindeutig belegbar ist, dass die Durchführung eines PSA-gestützten Screenings und damit verbundene Risiken diagnostischer und therapeutischer Konsequenzen durch eine Lebensverlängerung aufgewogen werden (Interdisziplinäre Leitlinie Prostatakarzinom 2011).

Literatur

  1. Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Derbe B, Zerbib M (2005) Negative Prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI nad magnetic resonance spectroscopy imaging (MRSI) a useful tool. Eur Urol 47: 582–586PubMedCrossRefGoogle Scholar
  2. Bastacky SJ, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI (1995) Pathological features of hereditary prostate cancer. J Urol 153:987–992PubMedCrossRefGoogle Scholar
  3. Beske F, Katalinic A, Peters E, Pritzukleit R (2009) Morbiditätsprognose 2050, Bd 114. Ausgewählte Krankheiten für Deutschland, Brandenburg und Scchleswig Hollstein. Schriftenreihe/Fritz Beske Institut für Gesundheits-System-Forschung, KielGoogle Scholar
  4. Bögermann C, Loertzner H. Hammerer P, Fonara P, Graefen M, Rübben H (2010) Probleme, Zielsetzung und Inhalt der Früherkennung beim Prostatakarzinom. Urologe 49: 181–189CrossRefGoogle Scholar
  5. Bolla M, Collette L, Blank L et al. (2002) Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 360: 103–06PubMedCrossRefGoogle Scholar
  6. Bolla M, Gonzalez D, Warde P et al. (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and Goserelin. N Engl J Med 337:295–300PubMedCrossRefGoogle Scholar
  7. Bonney W, Sched AR, Timberlake DS (1998) Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and metaanalysis of randomized trials. J Urol 160:1754–1760PubMedCrossRefGoogle Scholar
  8. Brawer MK, Chetner MP, (1997) Campell´s urology. Saunders, Philadelpia: 2506–2518Google Scholar
  9. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI (2006) Validation of a nomogram predicting the probability of lymph node invaison based on the extent of pelvic lymphadenectomy in patinets with clinicallylocaliced prostate cancer. BJU 98: 788–793CrossRefGoogle Scholar
  10. Brockhaus: Nobelpreise, Chronik herausragender Leistungen.1. Auflage. S 616Google Scholar
  11. Budach V, (2008) Stellungnahme der Deutschen Gesellschaft für Radioonkologie e. V. zur Strahlentherapie mit Protonen in DeutschlandGoogle Scholar
  12. Cahon O, Zelefsky MJ, Shippy A, Chan H et al. (2008) Ultra-high dose (86.4Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71: 330–337CrossRefGoogle Scholar
  13. Catalona JW, Whitemore WF (1989) New staging systems for prostate cancaer. Journal of Urology 142: 1302–1304PubMedGoogle Scholar
  14. Chun FK, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V, Gallina A, Walz J, Haese A, Steuber T, Erbersdobler A, Schlomm T, Ahyai SA, Currlin E, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz PI, (2007) Development and external validationof an extended 10-core biopsy nomogram. Eur Urol 52: 436–444PubMedCrossRefGoogle Scholar
  15. Coen JJ, Bae K, Zietman L, Patel B et al. (2010) cute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: Initial report of American College of Radiology pahse II Study 03-12. Int J Radiat Oncol Biol Phys XX : 1–5Google Scholar
  16. Dennis LK, Dawson DV, Resnik MI. Vasektloie and the risk of prostate cancer: a meta-analysis examining vasektomie status, age at vasektmy and time since vasectomy. (2002) Prostate Cancer Prostatic Dis. 5: 193–203Google Scholar
  17. Didinger B, Schulz-Ertner D, Wannenmacher M, Debus J (2003) Moderne Techniken in der Radiotherapie des Prostatakarzinoms. Radiologe 43 (6):448–454PubMedCrossRefGoogle Scholar
  18. Emami B, Lyman J, Brown A et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMedCrossRefGoogle Scholar
  19. Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, sachsen-Anhalt und der Freistaaten Sachsen und Thüringen. Krebsinzidenz 2001 und 2002 im Erfassungsgebiet des Gemeinsamen Krebsregisters. Jahresbericht 2005Google Scholar
  20. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother 50:125–130Google Scholar
  21. Gleason DF (1992) Histologie grading of prostate cancer: a perspective. Hum Pathol 23:273–279PubMedCrossRefGoogle Scholar
  22. Hanks GE (2000) RTOG 92-02, RTOG 85-31, and EORTC 22863 indicate the standard of practice for locally advanced and high grade prostate cancer. Radiother Oncol 55 S1:11–12Google Scholar
  23. Helpap B, Böcking A, Dhom G, Kastendieck R, Leistenschneider W, Müller HA (1985) Klassifikation, histologisches und zytologisches Grading sowie Regressionsgrading des Prostatakarzinoms. Eine Empfehlung des pathologisch-urologischen Arbeitskreises „Prostatakarzinom“. Pathologe 6:3–7PubMedGoogle Scholar
  24. Herbert JR, Hurley B, Marshall J, Priore R, Byers T, Rzepka T, Metlin C, Pontes JE, (1998) Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 90: 1637–1647CrossRefGoogle Scholar
  25. Herrell SD, Trachtenberg J, Theodorescu D (1997) Staging pelvic lymphadenectomy for localized carcinoma of the prostate: a comparison of 3 surgical techniques. J Urol 157: 1337–1339PubMedCrossRefGoogle Scholar
  26. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms (2011) Deutsche Gesellschaft für UrologieGoogle Scholar
  27. Jewett HJ (1975) The staus of radical prostatectomy for stages A and B prostatic cancer. Urol Clin N Am: 2, 105–124Google Scholar
  28. Johns LE, Houlston RS (2003) A systemic review and meta analysis of familial prostate cancer risk. BJU Int 91:789–794PubMedCrossRefGoogle Scholar
  29. Kuban DA, Tucker SL, Dong L et al. (2008) Long-term results of the M.D. Anderson randomized dose-esclaltion trial for prostate cancer. Int J Radiat Oncol Biol Phys 70: 67–74PubMedCrossRefGoogle Scholar
  30. Loeb S, Smith ND, Roehl KA, Catalona WJ (2007) Intermediate-term potency, continence and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007: 1170–1175Google Scholar
  31. Medical Research Council Prostate Working Party Investigators Group. (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Brit. Journal of Urology 79, 235–246Google Scholar
  32. Meerleer GO de, Vakaet LAML, Gersem WRT de Jr., Wagter CD, Naeyer B de, Neve W de (2000) Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 47:639–648PubMedCrossRefGoogle Scholar
  33. Morris DE, Bahman E, Mauch PM, Konski AA et al. (2005) Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62: 3–19PubMedCrossRefGoogle Scholar
  34. Morris DE, Emami B, Mauch PM et al. (2005) Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62:3–19PubMedCrossRefGoogle Scholar
  35. Mostofi FK, Sesterhenn IA, Sobin LH (1980) Histological typing of prostate tumours. International histological classification of tumours. No. 22 World Health Organisation, GenevaGoogle Scholar
  36. Müller HA, Altenähr E, Böcking A, Dhom G, Faul P, Göttinger H (1980) Über Klassifikation und Grading des Prostatakarzinoms. Verh Dtsch Ges Path 64:609–611Google Scholar
  37. Paulson DF, Lin GH, Hinshaw W, Stephani S (1982) The Uro-Oncology Research Group. Radical surgery vs. Radiotherapy for adenocarcinoma of the prostate. J Urol 128:502–504PubMedGoogle Scholar
  38. Peeters STH, Heemsbergen WD, van Putten WLJ, Slot Annerie et al. (2005) Acute and late complcations after Radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68Gy to 78Gy. Int J Radiat Oncol Biol Phys 61: 1019–1034PubMedCrossRefGoogle Scholar
  39. Perna L, Alongi F et al. (2010) Predictors of akute bowel toxicity in patients treated with IMRT whole pelvis irradiation after prostatectomy. Radiation & Oncology 97: 71–75CrossRefGoogle Scholar
  40. Pilepich MV, Caplan R, Byhardt RW et al. (1997) Phase III trial of androgen suppression using Goserelin in unfavorableprognosis carcinoma of the prostate treated with definitive radiotherapy: Report of radiation therapy oncology Group Protocol 85–31. J Clin Oncol 15:1013–1021PubMedGoogle Scholar
  41. Pilepich MV, Winter K, Lawton CA (2005) Androgen suppression adjuvant to definitive radiotherapy in prostatecarcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285–1290PubMedCrossRefGoogle Scholar
  42. Robert Koch-Institut (RKI), Gesellschaft der epidemiologischen Krebsregister in Deutschland (GEKID). Krebs in Deutschland 2003–2004Google Scholar
  43. Sathya JR, Davis IR, Julian JA et al. (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23:1192–1199PubMedCrossRefGoogle Scholar
  44. Slater JD, Rossi CJ Jr., Yonemoto LT et al. (2004) Proton therapy for prostate cancer: the initial Loma Linda university experience. Int J Radiat Oncol Biol Phys 59:348–352PubMedCrossRefGoogle Scholar
  45. UICC (1998) Prostata. In: Hermanek P, Sobin LH, Wagner G, Wittekind Ch (Hrsg.) TNM-Atlas. 4. Aufl. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  46. Van Poppel H, Vekemans K, Da Pozzo L et al. (2006) Radical prostatectomy for lokal advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J cancer 2006: 1062–1067Google Scholar
  47. Vargas C, Fryer A, Mahajan C, Indelicato D et al. (2008) Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70: 744–751PubMedCrossRefGoogle Scholar
  48. Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, Lau WK, NG WS, Cheng CW (2004) Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. Journ. Urol. 1482–1486Google Scholar
  49. Wiegel T, (2010), Positiver Schnittrand – Wie gehen wir damit um? Aus der Sicht des Strahlentherapeuten. Journal für Urologie und Urogynäkologie 17: 11–12Google Scholar
  50. Zamboglou N, Tselis N, Baltas D, Buhleier T, Martin T, Milickovic N, Papaioannou S, Ackermann H, Tunn UW (2013) High-Dose-Rate Interstitial Brachytherapy for Clinically Lokalized Prostate Cancer: Treatment evaluation and Mature Results. International Journal of Radiation Oncology Biology Physics 85, 672–678CrossRefGoogle Scholar
  51. Zeegers MP, Jellema A, Oster H (2003) Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoms: a meta-analysis. Cancer 97: 1894–1903PubMedCrossRefGoogle Scholar
  52. Zelefsky MJ, Chan H, Hunt M, Yamada Y et al. (2006) Long-Term outcome of high dose Intensity Modulated Radiation Therapy for patients with clinically localized Prostate cancer. Journal of Urology 176, 1415–1419PubMedCrossRefGoogle Scholar
  53. Zietman L, Bae K, Slater JD, William U et al. (2010) Randomized trial comparing convetional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the Prostate: Long trem results from proton radiation oncology group. Journal of Clinical Oncology 28, 1106–1111PubMedCrossRefGoogle Scholar
  54. Zietmann AL, DeSilvio ML, Slater JD et al. (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localiced adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294: 1233–1239CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Th. Buhleier
    • 1
  • D. Zierhut
    • 1
  1. 1.Klinik für Radioonkologie und StrahlentherapieKlinikum HanauHanauDeutschland

Personalised recommendations